Most clinical drug regimens for irinotecan (CPT-11 [Camptosar]) have been empirically based on classic in vivo pharmacokinetic and pharmacodynamic considerations. We propose an alternative approach that attempts to
Shousong Cao, MD
Advertisement
Articles by Shousong Cao, MD
Advertisement
Latest Updated Articles
- Rational Design of Irinotecan Administration Based on Preclinical Models
Published: August 1st 1998 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
4
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
5
